Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DapaHeart: Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion
NCT03313752Phase 3Completed
- Sponsor
- Andrea Giaccari
- Start
- Dec 2017
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), sponsored by Andrea Giaccari. Started Dec 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03313752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03313752.